<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069238</url>
  </required_header>
  <id_info>
    <org_study_id>030304</org_study_id>
    <secondary_id>03-C-0304</secondary_id>
    <nct_id>NCT00069238</nct_id>
    <nct_alias>NCT00072254</nct_alias>
  </id_info>
  <brief_title>Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas</brief_title>
  <official_title>Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      The paradigm of combining therapeutic agents with non-overlapping toxicities for the
      treatment of malignancy produces clinical remissions and cures in a number of tumor types.

      A new class of agents, humanized and chimerized monoclonal antibodies, typically have little
      or no hematopoietic toxicity and can be readily combined with full doses of cytotoxic
      chemotherapy. It has become clear that in certain lymphomas and breast cancers, the
      combination of monoclonal antibodies and chemotherapy improves response rate and the quality
      of the response compared with that achieved by treatment with either agent alone.

      The clinical outcome for patients with T-cell non-Hodgkins lymphoma is significantly inferior
      to the outcome of patients with B-cell non-Hodgkin s lymphoma. In most reports less than 20%
      of patients with T cell lymphoid malignancies remain free of disease at 5 years.

      Objectives:

      Determine the toxicity of Alemtuzumab and etoposide, prednisone, vincristine,
      cyclophosphamide, doxorubicin (EPOCH) chemotherapy in untreated cluster of differentiation 52
      (CD52)-expressing T and natural killer (NK) lymphoid malignancies.

      Determine the maximum tolerated dose of Alemtuzumab administered in combination with EPOCH
      chemotherapy.

      Determine in a preliminary fashion the anti-tumor activity of the combination of Alemtuzumab
      and EPOCH chemotherapy.

      Eligibility:

      CD52-expressing lymphoid malignancy.

      Patients with chemotherapy naive aggressive T &amp; NK lymphomas. Patients with alk-positive
      anaplastic large cell lymphoma and patients with T cell precursor disease are not eligible.

      Age greater than or equal to 17 years.

      Adequate organ function, unless impairment due to respective organ involvement by tumor.

      No active symptomatic ischemic heart disease, myocardial infarction or congestive heart.
      failure within the past year.

      Human immunodeficiency virus (HIV) negative.

      Not pregnant or nursing.

      Design:

      Three dose levels of Alemtuzumab will be evaluated to determine the toxicity profile and in a
      preliminary fashion the antitumor activity of the combination with Dose-Adjusted EPOCH.

      Three dose levels of Alemtuzumab will be explored, in cohorts of three to six patients each.
      Patients will receive either 30, 60, or 90 mg of Alemtuzumab on day 1 of therapy, followed by
      dose-adjusted EPOCH chemotherapy days 1-5.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      The paradigm of combining therapeutic agents with non-overlapping toxicities for the
      treatment of malignancy produces clinical remissions and cures in a number of tumor types.

      A new class of agents, humanized and chimerized monoclonal antibodies, typically have little
      or no hematopoietic toxicity and can be readily combined with full doses of cytotoxic
      chemotherapy. It has become clear that in certain lymphomas and breast cancers, the
      combination of monoclonal antibodies and chemotherapy improves response rate and the quality
      of the response compared with that achieved by treatment with either agent alone.

      The clinical outcome for patients with T-cell non-Hodgkins lymphoma is significantly inferior
      to the outcome of patients with B-cell non-Hodgkins lymphoma. In most reports less than 20%
      of patients with T cell lymphoid malignancies remain free of disease at 5 years.

      Objective:

      Determine the toxicity and maximum tolerated dose (MTD) of Alemtuzumab and EPOCH chemotherapy
      in untreated cluster of differentiation 52 (CD52)-expressing T and natural killer (NK)
      lymphoid malignancies

      Eligibility:

        -  CD52-expressing lymphoid malignancy.

        -  Patients with chemotherapy naive aggressive T &amp; NK lymphomas. Patients with alk-positive
           anaplastic large cell lymphoma and patients with T cell precursor disease are not
           eligible.

        -  Age greater than or equal to 17 years.

        -  Adequate organ function, unless impairment due to respective organ involvement by tumor.

        -  No active symptomatic ischemic heart disease, myocardial infarction or congestive heart.
           failure within the past year.

        -  Human immunodeficiency virus (HIV) negative.

        -  Not pregnant or nursing.

      Design:

      Three dose levels of Alemtuzumab will be evaluated to determine the toxicity profile and in a
      preliminary fashion the antitumor activity of the combination with Dose-Adjusted etoposide,
      prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH).

      Three dose levels of Alemtuzumab will be explored, in cohorts of three to six patients each.
      Patients will receive either 30, 60, or 90 mg of Alemtuzumab on day 1 of therapy, followed by
      dose-adjusted EPOCH chemotherapy days 1-5.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2003</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 11, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Alemtuzumab</measure>
    <time_frame>Evaluation of dose limiting toxicity was done at the end of each cycle or every 21 days.</time_frame>
    <description>MTD was achieved by increasing doses of Alemtuzumab on three cohorts. Cohort 1 received 30mg of Alemtuzumab, cohort 2 received 60mg of Alemtuzumab, and cohort 3 received 90mg of Alemtuzumab intravenously every 3 weeks for up to 6 cycles. The MTD reflects the highest dose of Alemtuzumab in which no more than 1 of 6 participants entered at a specific dose level experienced a dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>67 months and 9 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>For patients with response:Restage sites of disease every (q) 3 months for the first year, then q4 months for the second year, and then q6 months for the next 3 years, and yearly thereafter. The timing for these visits may be adjusted + 2 months.</time_frame>
    <description>Response was measured by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Complete remission (CR) is complete disappearance of all detectable clinical and radiographic evidence of disease. Complete response unconfirmed (Cru)is as per complete remission criterion except that if a residual node is greater than 1.5cm, it must have decreased by greater than 75% in the sum of the products of the perpendicular diameters (SPD). Partial response (PR) is ≥50% decrease in the SPD of 6 largest dominant nodes or nodal masses. Progressive disease (PD) is ≥50% increase from the nadir in the SPD of any previously identified abnormal node for PRS or non-responders. Stable disease (SD) is less than a PR but not progressive disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Lymphoma, T-Cell</condition>
  <condition>Lymphoma, Extranodal NK-T-Cell</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab (Campath)</intervention_name>
    <description>Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.</description>
    <arm_group_label>Alemtuzumab Dose Escalation</arm_group_label>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPOCH</intervention_name>
    <description>Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.</description>
    <arm_group_label>Alemtuzumab Dose Escalation</arm_group_label>
    <other_name>Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  ELIGIBILITY CRITERIA:

        Cluster of differentiation 52 (CD52)-expressing lymphoid malignancy, confirmed by pathology
        or flow cytometry staff of the Hematopathology Section, Laboratory of Pathology, National
        Cancer Institute (NCI). Patients with T &amp; natural killer (NK) cell malignancy without
        accessible tissue for flow cytometry analysis may be treated on this study.

        Patients with chemotherapy naive aggressive T &amp; NK lymphomas, including but not limited to
        peripheral T cell lymphoma (not otherwise specified (nos)), gamma-delta hepatosplenic T
        cell lymphoma, subcutaneous panniculitis-like T cell, NK-T cell lymphoma confirmed by
        pathology or flow cytometry staff of the Hematopathology Section, Laboratory of Pathology,
        NCI. Patients with alk-positive anaplastic large cell lymphoma and patients with T cell
        precursor disease are not eligible.

        Age greater than or equal to 17 years.

        Laboratory tests: Creatinine less than or equal to 1.5 mg/dL or creatinine clearance
        greater than or equal to 60 ml/min; bilirubin less than 2.0 mg/dl unless due to Gilbert's,
        aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3
        times upper limit of normal (ULN) (AST and ALT is less than or equal to 6 times ULN for
        patients on hyperalimentation for whom these abnormalities are felt to be due to the
        hyperalimentation) and; absolute neutrophil count (ANC) is greater than or equal to
        1000/mm(3), platelet greater than or equal to 75,000/mm(3); unless impairment due to
        respective organ involvement by tumor.

        No active symptomatic ischemic heart disease, myocardial infarction or congestive heart
        failure within the past year.

        Human immunodeficiency virus (HIV) negative, because of the unknown effects of combined
        therapy with chemotherapy and an immunosuppressive agent on HIV progression.

        Signed informed consent.

        Willing to use contraception.

        Not pregnant or nursing, because of the unknown effects of Alemtuzumab on the developing
        fetus and infant.

        No serious underlying medical condition or infection that would contraindicate treatment.
        Patients with central nervous system (CNS) involvement are eligible for treatment on this
        study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wyndham H Wilson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2003-C-0304.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996 Dec 15;98(12):2819-26.</citation>
    <PMID>8981930</PMID>
  </reference>
  <reference>
    <citation>Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5):1361-92. Review.</citation>
    <PMID>8068936</PMID>
  </reference>
  <reference>
    <citation>A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997 Jun 1;89(11):3909-18.</citation>
    <PMID>9166827</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2003</study_first_submitted>
  <study_first_submitted_qc>September 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2003</study_first_posted>
  <results_first_submitted>October 7, 2015</results_first_submitted>
  <results_first_submitted_qc>December 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2016</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Wyndham Wilson, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>T-Cell Lymphoma</keyword>
  <keyword>NK -Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alemtuzumab 30 mg</title>
          <description>Alemtuzumab (Campath) 30mg intravenous (IV) on day 1 of therapy, followed by etoposide (50mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), prednisone (60mg/m(2) day by mouth (PO) day 0-5), vincristine (0.4mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), cyclophosphamide (750mg/m(2) day intravenous day 5), doxorubicin (10mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), (EPOCH) days 1-5 every 3 weeks for up to 6 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Alemtuzumab 60 mg</title>
          <description>Alemtuzumab (Campath) 60mg intravenous (IV) on day 1 of therapy, followed by etoposide (50mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), prednisone (60mg/m(2) day by mouth (PO) day 0-5), vincristine (0.4mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), cyclophosphamide (750mg/m(2) day intravenous day 5), doxorubicin (10mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), (EPOCH) days 1-5 every 3 weeks for up to 6 cycles.</description>
        </group>
        <group group_id="P3">
          <title>Alemtuzumab 90 mg</title>
          <description>Alemtuzumab (Campath) 90mg intravenous (IV) on day 1 of therapy, followed by etoposide (50mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), prednisone (60mg/m(2) day by mouth (PO) day 0-5), vincristine (0.4mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), cyclophosphamide (750mg/m(2) day intravenous day 5), doxorubicin (10mg/m(2) day continuous intravenous (CIV) day 1-4 (96 hours)), (EPOCH) days 1-5 every 3 weeks for up to 6 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort 1 - Dose Level 1 (Weeks 1 - 18)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cohort 2 - Dose Level 2 (Weeks 1-18)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cohort 3 - Dose Level 3 (Weeks 1-18)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who received at least one dose of Alemtuzumab (Campath) 30mg, 60mg, or 90mg on day 1 of therapy followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy intravenously every 3 weeks for up to 6 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.52" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Alemtuzumab</title>
        <description>MTD was achieved by increasing doses of Alemtuzumab on three cohorts. Cohort 1 received 30mg of Alemtuzumab, cohort 2 received 60mg of Alemtuzumab, and cohort 3 received 90mg of Alemtuzumab intravenously every 3 weeks for up to 6 cycles. The MTD reflects the highest dose of Alemtuzumab in which no more than 1 of 6 participants entered at a specific dose level experienced a dose limiting toxicity (DLT).</description>
        <time_frame>Evaluation of dose limiting toxicity was done at the end of each cycle or every 21 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least one dose of Alemtuzumab (Campath) 30mg, 60mg, or 90mg on day 1 of therapy followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy intravenously every 3 weeks for up to 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Alemtuzumab</title>
          <description>MTD was achieved by increasing doses of Alemtuzumab on three cohorts. Cohort 1 received 30mg of Alemtuzumab, cohort 2 received 60mg of Alemtuzumab, and cohort 3 received 90mg of Alemtuzumab intravenously every 3 weeks for up to 6 cycles. The MTD reflects the highest dose of Alemtuzumab in which no more than 1 of 6 participants entered at a specific dose level experienced a dose limiting toxicity (DLT).</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>67 months and 9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least one dose of Alemtuzumab (Campath) 30mg, 60mg, or 90mg on day 1 of therapy followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy intravenously every 3 weeks for up to 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response</title>
        <description>Response was measured by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Complete remission (CR) is complete disappearance of all detectable clinical and radiographic evidence of disease. Complete response unconfirmed (Cru)is as per complete remission criterion except that if a residual node is greater than 1.5cm, it must have decreased by greater than 75% in the sum of the products of the perpendicular diameters (SPD). Partial response (PR) is ≥50% decrease in the SPD of 6 largest dominant nodes or nodal masses. Progressive disease (PD) is ≥50% increase from the nadir in the SPD of any previously identified abnormal node for PRS or non-responders. Stable disease (SD) is less than a PR but not progressive disease.</description>
        <time_frame>For patients with response:Restage sites of disease every (q) 3 months for the first year, then q4 months for the second year, and then q6 months for the next 3 years, and yearly thereafter. The timing for these visits may be adjusted + 2 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least one dose of Alemtuzumab (Campath) 30mg, 60mg, or 90mg on day 1 of therapy followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy intravenously every 3 weeks for up to 6 cycles.
The adverse events are not reported per dose level because we normally look at all adverse events together irrespective of the dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response</title>
          <description>Response was measured by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Complete remission (CR) is complete disappearance of all detectable clinical and radiographic evidence of disease. Complete response unconfirmed (Cru)is as per complete remission criterion except that if a residual node is greater than 1.5cm, it must have decreased by greater than 75% in the sum of the products of the perpendicular diameters (SPD). Partial response (PR) is ≥50% decrease in the SPD of 6 largest dominant nodes or nodal masses. Progressive disease (PD) is ≥50% increase from the nadir in the SPD of any previously identified abnormal node for PRS or non-responders. Stable disease (SD) is less than a PR but not progressive disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response Unconfirmed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>67 months and 9 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants who received at least one dose of Alemtuzumab (Campath) 30mg, 60mg, or 90mg on day 1 of therapy followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy intravenously every 3 weeks for up to 6 cycles.
The adverse events are not reported per dose level because we normally look at all adverse events together irrespective of the dose level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, GI:: Upper GI Not otherwise specified (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH:: Death not associated with CTCAE term:: Death Not otherwise specified (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DEATH:: Death not associated with CTCAE term:: Disease progression NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION:: Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L):: Blood</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L):: Brain (encephalitis, infectious)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Lung (pneumonia)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with unknown ANC:: Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>AUDITORY/EAR:: Otitis, middle ear (non-infectious)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Bone marrow cellularity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Hemoglobin</sub_title>
                <counts group_id="E1" events="101" subjects_affected="29" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Leukocytes (total white blood count (WBC))</sub_title>
                <counts group_id="E1" events="121" subjects_affected="30" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Lymphopenia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="30" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>Absolute neutrophil count/absolute granulocyte count (ANC/AGC)</description>
                <counts group_id="E1" events="116" subjects_affected="30" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA:: Supraventricular and nodal arrhythmia:: Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>COAGULATION:: PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mucositis/stomatitis (functional/symptomatic):: Esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>LYMPHATICS:: Edema: head and neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>LYMPHATICS:: Edema: limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>LYMPHATICS:: Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Platelets</sub_title>
                <counts group_id="E1" events="102" subjects_affected="28" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA:: Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA:: Supraventricular and nodal arrhythmia:: Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA:: Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC GENERAL:: Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC GENERAL:: Hypotension</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>AUDITORY/EAR:: Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR/VISUAL:: Ocular/Visual - Other (Specify, red eyes)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Ophthalmoplegia/diplopia (double vision)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Vision-blurred vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Vision-photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Watery eye (epiphora, tearing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL:: Ocular/Visual - Other (Specify, dilated, non-reactive R.pupil</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL:: Anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Constipation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dental: teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Diarrhea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Gastrointestinal - Other (Specify, duodenitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mucositis/stomatitis (clinical exam):: Oral cavity</sub_title>
                <counts group_id="E1" events="33" subjects_affected="20" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mucositis/stomatitis (clinical exam):: Pharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mucositis/stomatitis (functional/symptomatic):: Oral cavity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Nausea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, GI:: Lower GI NOS</sub_title>
                <description>Not otherwise specified (NOS)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, GI:: Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, GI:: Upper GI NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection - Other (Specify, BLOOD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Abdomen Not otherwise specified (NOS)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Dental/teeth/peridontal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Rectum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Gastrointestinal - Other (Specify, tongue-blue spot)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, Pain: jaw pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, Pain:teeth)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, Pain: tooth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA:: Supraventricular and nodal arrhythmia:: Supraventricular arrhythmia NOS</sub_title>
                <description>Not otherwise specified (NOS)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA:: Supraventricular and nodal arrhythmia:: Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS</sub_title>
                <description>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Rigors/chills</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Weight loss</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DEATH:: Death not associated with CTCAE term:: Death NOS</sub_title>
                <description>Common Terminology Criteria in Adverse Events (CTCAE)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DEATH:: Death not associated with CTCAE term:: Disease progression NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage/Bleeding - Other (Specify, R. neck after picc line)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, L wrist)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION:: Infection(documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Abdomen NOS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Bladder (urinary)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Blood</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Brain (encephalitis, infectious)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Mucosa</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Spleen</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(Absolute neutrophil count (ANC) &lt;1.0 x 10e9/L):: Urinary tract NOS</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Vein</description>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with normal ANC or Grade 1 or 2 neutrophils:: Blood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with normal ANC or Grade 1 or 2 neutrophils:: Oral cavity-gums (gingivitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with normal ANC or Grade 1 or 2 neutrophils:: Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with normal ANC or Grade 1 or 2 neutrophils:: Urinary tract NOS</sub_title>
                <description>Not otherwise specified (NOS)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with unknown ANC:: Oral cavity-gums (gingivitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with unknown ANC:: Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, pulmonary/upper respiratory:: Nose</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <description>alanine aminotransferase (ALT), serum glutamic pyruvic transaminase (SGPT)</description>
                <counts group_id="E1" events="38" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <description>aspartate aminotransferase (AST), serum glutamic oxaloacetic transaminase (SGOT)</description>
                <counts group_id="E1" events="29" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="49" subjects_affected="20" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="44" subjects_affected="19" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="47" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="30" subjects_affected="15" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Wound</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with normal ANC or Grade 1 or 2 neutrophils:: Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection with unknown ANC:: Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE:: Arthritis (non-septic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE:: Joint-effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE:: Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <description>Extremity-lower</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE:: Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <description>Whole body/generalized</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE:: Musculoskeletal/Soft Tissue - Other (Specify, __)</sub_title>
                <description>cervical spine range of motion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE:: Soft tissue necrosis:: Extremity-lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Back</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Bone</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Buttock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Extremity-limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Joint</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Muscle</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, lumbar puncture (LP) site)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, Pain L big toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Catheter-related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Cecum</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Colon</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Conjunctiva</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils</sub_title>
                <description>(ANC &lt;1.0 x 10e9/L):: Lung (pneumonia)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Laryngeal nerve dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Mood alteration:: Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Mood alteration:: Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Mood alteration:: Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Neuropathy: motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Syncope (fainting)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Head/headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, GU:: Bladder</sub_title>
                <description>Genitourinary (GU)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, GU:: Urinary NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Cystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Incontinence, urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Obstruction, GU:: Ureter</sub_title>
                <description>Genitourinary (GU)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN:: Pain - Other (Specify, Pain:groin)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Hemorrhage, pulmonary/upper respiratory:: Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain:: Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY:: Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dermatology/Skin - Other (Specify, excoriation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Hyperpigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Nail changes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Pruritus/itching</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Rash/desquamation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING:: Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASCULAR:: Phlebitis (including superficial thrombosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VASCULAR:: Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VASCULAR:: Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wyndham WIlson</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-435-2415</phone>
      <email>wilsonw@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

